| Literature DB >> 34611232 |
Mengistu Hailemariam1, Tsegaye Alemayehu2, Bereket Tadesse3, Netsanete Nigussie3, Asnakech Agegnehu3, Techilo Habtemariam3, Mulubrhan Ali2, Enkosilassie Mitiku3, Elshaday Azerefegne3.
Abstract
Currently, antibiotic-resistant bacterial infections are a challenge for the health care system. Although physicians demand timely drug resistance data to guide empirical treatment, local data is rather scarce. Hence, this study performed a retrospective analysis of microbiological findings at the Hawassa public hospital. Secondary data were retrieved to assess the prevalence and level of drug resistance for the most common bacterial isolates from clinical samples processed at Hawassa University Comprehensive Specialized Hospital. Out of 1085 clinical samples processed in the microbiology laboratory, the prevalence of bacterial infection was 32.6%. Bacterial bloodstream infection was higher in children than in adults (OR, 4; 95% CI 1.8-14.6; p = 0.005). E. coli and K. pneumoniae were the commonest bacterial isolate both in children (36.8%, 26.3%) and in adults (33.3%, 26.7%) from the urine sample while, the leading bacteria identified from the CSF sample was P. aeruginosa, 37% in children and 43% in adult. In this study, all identified bacterial isolates were multi-drug resistant (MDR) ranging from 50 to 91%. The highest proportion of MDR was S. aureus 91.1 followed by K. pneumoniae 87.6%. Since the nationwide investigation of bacterial isolate, and drug resistance is rare in Ethiopia, a report from such type of local surveillance is highly useful to guide empirical therapy by providing awareness on the level resistance of isolates.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34611232 PMCID: PMC8492677 DOI: 10.1038/s41598-021-99272-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Age and sex distribution of patients with rate of infection.
| Age and sex | Positive n (%) | Negative n (%) | Total n (%) | X2 ( |
|---|---|---|---|---|
| Male | 240 (67.8) | 460 (62.9) | 700 (64.5) | 2.5 (0.11) |
| Female | 114 (32.2) | 271 (37.1) | 385 (35.5) | |
| 0–4 | 233 (65.8) | 432 (59.1) | 665 (61.3) | |
| 5–9 | 28 (7.9) | 81 (11.1) | 109 (10.0) | |
| 10–19 | 45 (12.7) | 98 (13.4) | 143 (13.2) | 8 (0.154) |
| 20–29 | 18 (5.1) | 61 (8.3) | 79 (7.3) | |
| 30–39 | 10 (2.8) | 23 (3.1) | 33 (3.0) | |
| > 40 | 20 (5.6) | 36 (4.9) | 56 (5.2) | |
| Total | 354 (32.6) | 731 (67.4) | 1085 (100) | |
Isolates from main infection sits in children and adults.
| Infection | Pathogen | Children, n (%) | Adults, n (%) | Total, n (%) |
|---|---|---|---|---|
| UTI | 28/76 (36.8) | 5/15 (33.3) | 33/91 (36.3) | |
| 20 (26.3) | 4 (26.7) | 24 (26.4) | ||
| 8 (10.6) | 1 (6.7) | 9 (9) | ||
| Others | 20 (26.3) | 5 (33.3) | 25 (27.3) | |
| CSF infection | 10/27 (37) | 3/7 (42.8) | 13/34 (38.2) | |
| 9 (33) | 1 (14.3) | 10 (29.4) | ||
| 4 (15) | 2 (28.6) | 6 (17.6) | ||
| Others | 4 (15) | 1 (14.3) | 5 (14.8) | |
| Bloodstream infection | 31/105 (29.5) | 3/5 (60.0) | 34/110 (31) | |
| 27 (25.7) | – | 27 (24.5) | ||
| 21 (20) | 1 (20) | 22 (20) | ||
| Others | 26 (24.8) | 1 (20) | 27 (24.5) | |
| Others | 22/91 (24.2) | 10/28 (35.7) | 32/119 (26.8) | |
| 15 (16.4) | 6 (21.4) | 21 (17.5) | ||
| 13 (14.3) | 2 (7.1) | 15 (12.5) | ||
| CONS | 10 (11.1) | 3 (10.7) | 13 (11) | |
| Others | 31 (34) | 7 (25.2) | 38 (32) | |
| Total | 299 (84.5) | 55 (15.5) | 354 (100) | |
Distribution of isolates from various infections in children and adult patients.
| Children, n (%) | Adults, n (%) | OR (95% CI) | ||
|---|---|---|---|---|
| Urinary tract infection | 76 (34) | 15 (30.3) | 1.2 (0.6–2.3) | 0.6 |
| CSF infection | 27 (9.3) | 7 (29.2) | 4 (1.5–10.5) | 0.005 |
| Bloodstream infection | 105 (61.4) | 5 (23.8) | 5.1 (1.8–14.6) | 0.002 |
| Others | 95 (43.0) | 30 (34.9) | 1.4 (0.85–2.3) | 0.19 |
| Total | 299 (100) | 55 (100) | – | – |
Non-susceptibility rates of the gram positive bacteria.
| Pathogen (n) | Antimicrobial non-susceptibility (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMC | SXT | CAZ | CTX | CAF | NIT | CRT | E | AMP | GN | MER | AMK | |
| 7 (12.5) | 17 (30.4) | 18 (32.2) | 3 (5.3) | 14 (25) | 6 (10.7) | 19 (34) | 29 (51.8) | 37 (66) | 31 (55.6) | 3 (5.3) | 12 (21.4) | |
| 14 (29.2) | 22 (45.8) | 11 (22.9) | 7 (14.6) | 20 (41.7 | 6 (12.5) | 1 (2.1) | 24 (50) | 31 (64.5) | 20 (41.7) | 6 (12.5) | 9 (18.7) | |
| 1 (14.5) | 4 (57.2) | 4 (57.2) | 4 (57.2) | 2 (28.5) | 2 (28.5) | 1 (14.5) | 4 (57.2) | 4 (57.2) | 6 (85.7) | 1 (14.2) | 2 (28.5) | |
| 2 (50) | 2 (50) | 1 (25) | 1 (25) | 3 (75) | 0 | 1 (25) | 3 (75) | – | 3 (75) | 0 | 1 (25) | |
CoNS, Coagulase Negative Staphylococci; AMC, Amoxicillin-Calvulanic acid (20/10 μg); SXT, cotrimoxazole (25 μg); CAZ, Ceftazidime (30 μg); CTX, cefotaxime(30 μg); CAF, Chloramaphenicol; NIT, nitrofurantoin (300 μg); CRT, ceftriaxone (30 μg); AMP, ampicillin (10 μg); E, Erythromycin (30 μg); GN, gentamicin (10 μg); MER, meropenem (10 μg); AMK, Amikacin (30 μg).
Non-susceptibility rates of the most prevalent gram negative bacteria.
| Pathogen (n) | Antimicrobial non-susceptibility (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMP | AMC | AMK | CAZ | CTX | SXT | CAF | CRO | GN | MER | CIP | |
| 33 (63.5) | 18 (34.6) | 20 (38.5) | 21 (40.4) | 8 (15.4) | 31 (59.6) | 14 (26.9) | 14 (26.9) | 22 (42.6) | 2 (3.8) | 28 (53.4) | |
| 76 (85.4) | 52 (58.4) | 56 (63) | 73 (82) | 24 (27) | 46 (51.6) | 19 (21.3) | 59 (66.3) | 19 (21.3) | 3 (3.3) | 72 (80.9) | |
| 29 (82.9) | 24 (68.6) | 18 (51.4) | 6 (17) | 21 (60) | 12 (34.3) | 9 (25.7) | 13 (37.1) | 4 (11.4) | 3 (8.6) | 24 (68.6) | |
| – | 6 (75) | 5 (62.5) | 3 (37.5) | 5 (62.5) | 2 (25) | 6 (75) | 6 (75) | 2 (25) | 0 | 6 (75) | |
| 4 (36.4) | 8 (72.7) | 4 (36.4) | 5 (45.5) | 6 (54.5) | 5 (45.5) | 3 (27.7) | 5 (45.5) | 5 (45.5) | 1 (9) | 4 (36.4) | |
| Acintobacter spp (17) | – | 8 (47) | 9 (52.9) | 15 (88) | 8 (47) | 5 (29.4) | 6 (35.3) | 6 (35.3) | 11 (64.7) | 3 (17.6) | 13 (76.5) |
AMP, ampicillin (10 μg); AMC, Amoxicillin-Calvulanic acid (20/10 μg); AMK, Amikacin(30 μg); CAZ, Ceftazidime (30 μg); CTX, cefotaxime(30 μg); SXT, cotrimoxazole (25 μg); CAF, Chloramphenicol; CRO, ceftriaxone (30 μg); GN, gentamicin (10 μg); MER, meropenem (10 μg); CIP, Ciprofloxacin (5 μg).
Antimicrobial resistance pattern of common pathogenic bacteria isolate from different sites of infections.
| Bacterial isolates | R0 | R1 | R2 | R3 | R4 | R5 | R > 5 | Total MDR |
|---|---|---|---|---|---|---|---|---|
| 4 (4.5) | 7 (1.1) | 15 (16.8) | 23 (25.8) | 19 (21.3) | 8 (8.9) | 13 (14.6) | 78 (87.6) | |
| 3 (5.4) | 2 (3.6) | 12 (21.4) | 6 (10.7) | 13 (25) | 11 (23.2) | 9 (16.1) | 51 (91.1) | |
| 5 (9.6) | 8 (15.4) | 6 (11.5) | 3 (5.8) | 1 (1.9) | 14 (26.9) | 15 (28.8) | 39 (75) | |
| CoNS (48) | 6 (12.5) | 5 (10.4) | 7 (14.6) | 11 (22.9) | 6 (12.5) | 7 (14.6) | 6 (12.5) | 37 (77.1) |
| 4 (11.4) | 6 (17.1) | 4 (11.4) | 5 (14.3) | 10 (28.6) | 4 (11.4) | 2 (5.7) | 25 (71.4) | |
| 2 (11.8) | 3 (17.6) | 2 (11.8) | 3 (17.6) | 6 (35.3) | 1 (5.9) | 0 | 12 (70.6) | |
| 1 (9.1) | 3 (27.3) | 1 (9.1) | 1 (9.1) | 3 (27.3) | 1 (9.1) | 1 (9.1) | 7 (63.6) | |
| 0 | 3 (37.5) | 1 (12.5) | 3 (37.5) | 1 (12.5) | 0 | 0 | 5 (62.5) | |
| 2 (28.6) | 1 (14.3) | 2 (28.6) | 1 (14.3) | 0 | 1 (14.3) | 0 | 5 (71.4) | |
| 1 (25) | 1 (25) | 0 | 0 | 2 (50) | 0 | 0 | 2 (50) |
R0: susceptible to all antimicrobials tested; R1, R2, R3, R4, R5, R > 5: Resistance to one, two, three, four, five, and more than five antimicrobials, respectively.